Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.indoco.com | |
Market Cap | 3,099.94 Cr. | |
Enterprise Value(EV) | 3,345.40 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 17.03 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 19.88 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.80 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 108.35 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 3.12 | Calculated using Price: 338.45 |
Dividend Yield | 0.67 | Period Ending 2022-03 |
No. of Shares Subscribed | 9.22 Cr. | 92,150,355 Shares |
FaceValue | 2 | |
Company Profile | ||
Indoco Remedies is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The Company caters to both domestic and International markets. Indoco has strengthened its wings in the international markets and offers complete solutions, including product development, manufacture and supply of Finished Dosages, APIs and Intermediates to generic companies worldwide. The company has a large basket of products backed by ANDAs / eCTD Dossiers and Drug Master Files (DMFs). Expertise in Research & Development, backward integration in API in select products, own CRO set-up, excellence in Finished Dosages manufacturing and a strong customer base will ensure consistent growth in the Company’s Domestic, as well as International business. |
1 Day |
|
+1.21% |
1 Week |
|
+3.12% |
1 Month |
|
-13.91% |
3 Month |
|
-6.89% |
6 Month |
|
-13.68% |
1 Year |
|
-10.32% |
2 Year |
|
+7.31% |
5 Year |
|
+25.33% |
10 Year |
|
+454.38% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 13.32 | 16.97 | 14.96 | 12.55 | 6.21 | -0.43 | 3.60 | 12.85 | 18.50 | |
Return on Capital Employed (%) | 16.84 | 20.63 | 16.72 | 11.80 | 7.62 | 1.23 | 5.78 | 15.67 | 23.33 | |
Return on Assets (%) | 8.17 | 10.52 | 9.15 | 7.22 | 3.42 | -0.24 | 1.96 | 7.23 | 10.63 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 457 | 519 | 577 | 651 | 675 | 661 | 680 | 769 | 905 | 970 | |
Non Curr. Liab. | 70 | 65 | 66 | 147 | 125 | 116 | 101 | 158 | 157 | 159 | |
Curr. Liab. | 202 | 262 | 303 | 390 | 417 | 446 | 459 | 407 | 518 | 536 | |
Minority Int. | 0 | ||||||||||
Equity & Liab. | 729 | 846 | 946 | 1,189 | 1,218 | 1,223 | 1,240 | 1,334 | 1,579 | 1,665 | |
Non Curr. Assets | 425 | 460 | 481 | 617 | 679 | 684 | 676 | 712 | 712 | 770 | |
Curr. Assets | 305 | 385 | 465 | 572 | 539 | 538 | 563 | 623 | 867 | 895 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 729 | 846 | 946 | 1,189 | 1,218 | 1,223 | 1,240 | 1,334 | 1,579 | 1,665 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 733 | 857 | 1,008 | 1,075 | 1,042 | 968 | 1,107 | 1,242 | 1,541 | 1,650 | |
Other Income | 4 | 2 | 4 | 6 | 8 | 7 | 5 | 9 | 7 | 2 | |
Total Income | 737 | 859 | 1,012 | 1,081 | 1,050 | 975 | 1,111 | 1,251 | 1,547 | 1,652 | |
Total Expenditure | -614 | -692 | -840 | -920 | -910 | -892 | -986 | -1,023 | -1,215 | -1,348 | |
PBIDT | 122 | 167 | 172 | 160 | 140 | 83 | 126 | 227 | 333 | 304 | |
Interest | -19 | -11 | -12 | -6 | -24 | -21 | -26 | -22 | -17 | -19 | |
Depreciation | -31 | -47 | -61 | -63 | -68 | -72 | -71 | -73 | -79 | -71 | |
Taxation | -14 | -27 | -17 | -14 | -7 | 6 | -4 | -39 | -82 | -57 | |
Exceptional Items | |||||||||||
PAT | 58 | 83 | 82 | 77 | 41 | -3 | 24 | 93 | 155 | 157 | |
Minority Interest | 0 | ||||||||||
Share Associate | 0 | ||||||||||
Other Related Items | 0 | ||||||||||
Consolidated Net Profit | 58 | 83 | 82 | 77 | 41 | -3 | 24 | 93 | 155 | 157 | |
Adjusted EPS | 6 | 9 | 9 | 8 | 4 | 0 | 3 | 10 | 17 | 17 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 69 | 99 | 109 | 112 | 89 | 123 | 132 | 123 | 82 | 174 | |
Cash Fr. Inv. | -43 | -41 | -88 | -111 | -171 | -135 | -104 | -56 | -67 | -121 | |
Cash Fr. Finan. | -24 | -59 | -20 | -2 | 132 | -39 | -16 | -64 | -30 | -44 | |
Net Change | 2 | -1 | 1 | 0 | 50 | -51 | 12 | 3 | -14 | 8 | |
Cash & Cash Eqvt | 11 | 10 | 10 | 10 | 60 | 9 | 21 | 24 | 9 | 17 |
Fri, 03 Feb 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are enclosing schedule for the Investor Call/ Institutional Investors Conference/Meetings. |
Thu, 02 Feb 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are enclosing schedule for the Investor Call/ Institutional Investors Conference/Meetings. |
Tue, 31 Jan 2023
Announcement under Regulation 30 (LODR)-Earnings Call Transcript Transcript of Earnings Conference Call for the quarter and nine months ended 31st December 2022 |
Tue, 07 Feb 2023 |
|
|
|
|
Mon, 06 Feb 2023 |
|